GeoVax Labs, Inc. (GOVX) Stock Price, Financials & Summary

Price chart

Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16

Key dataOct 16, 2026

Open$0.26

From 52W high−98.41%

Volume145491.00

Market cap$2.17M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 16, 2026

Open

$0.26

From 52W high

−98.41%

Volume

145491.00

Market cap

$2.17M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.0x

P/E (TTM)

—

RSI (14)

20.9

MomentumView details →

1D Return

−7.56%

YTD Return

−94.41%

SummaryUpdated Jun 1, 2026

GeoVax Labs, Inc. (NASDAQ:GOVX) is a clinical-stage biotechnology company founded in 1988 and headquartered in Smyrna, Georgia. The company went public in September 2020 and specializes in developing human vaccines and immunotherapies against infectious diseases and cancers using its proprietary modified vaccinia ankara virus-like particle (MVA-VLP) vaccine platform. GeoVax has established strategic partnerships with prestigious institutions including the National Institutes of Health, Centers for Disease Control and Prevention, U.S. Department of Defense, Emory University, University of Pittsburgh, and the Burnet Institute. The company has evolved from its early research focus to become a clinical-stage developer with multiple vaccine candidates in various phases of development.

Ask drillr about GeoVax Labs, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.0x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.2x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−1160.10%

ROA (TTM)

−439.95%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−100.00%

EPS YoY

+77.69%

FCF YoY

—

Revenue CAGR 3Y

+212.55%

EPS CAGR 3Y

+81.41%

EBITDA YoY

+16.79%

MomentumView details →

1D Return

−7.56%

YTD Return

−94.41%

1Y Return

−98.27%

RSI (14)

20.9

vs 50D SMA

−49.93%

vs 200D SMA

−83.68%

Capital & dividendView details →

Debt/Equity

0.18x

Current Ratio

1.54x

Quick Ratio

1.54x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.97

EPS Surprise

55.09%

Beats (12Q)

4/12

Next Q EPS Est

−$1.20

Avg Surprise (4Q)

−3.52%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−20.43M

Op. CF (TTM)

−18.37M

Next earningsNov 12, 2026 →

Latest newsMore news →

GeoVax Labs, Inc. signed an inducement letter on August 25, 2026, under which a holder agreed to exercise existing common stock purchase warrants for cash, in exchange for new warrants to purchase 200% of the exercised shares at $0.64 per share, raising approximately $3,646,482.49d ago

Similar companies

Clearside Biomedical, Inc.CLSD BioRestorative Therapies, Inc.BRTX Silexion Therapeutics Ltd.SLXN XORTX Therapeutics Inc.XRTX Estrella Immunopharma, Inc.ESLAW BioXcel Therapeutics, Inc.BTAI Find similar companies →

Latest newsMore news →

GeoVax Labs, Inc. received a notice from Nasdaq on August 27, 2026, stating it no longer complies with the minimum bid price requirement under Rule 5550(a)(2), and plans to request a hearing before the Nasdaq Hearings Panel before the September 3, 2026 deadline.49d ago GeoVax Labs, Inc. signed an inducement letter on August 25, 2026, under which a holder agreed to exercise existing common stock purchase warrants for cash, in exchange for new warrants to purchase 200% of the exercised shares at $0.64 per share, raising approximately $3,646,482.49d ago GeoVax Labs, Inc. entered into a warrant inducement private placement on May 8, 2026, issuing new common stock purchase warrants to existing warrant holders as an inducement for their cash exercise of outstanding warrants for 501,144 shares, raising approximately $595,000 in gross proceeds.163d ago